Search
Neurotech founder Adrian Trevisan (left) with chief executive Wolfgang Storf.

Neurotech makes solid ASX debut

A neuroscience-focused business that has been backed by the Perth-based Trevisan family has made a solid debut on the ASX after completing a $7 million initial public offering led by Azure Capital.

Neurotech International, based in Malta, provides medical solutions for the management of neurological disorders including autism spectrum disorder (ASD), epilepsy, anxiety and depression.

The company was founded by Adrian Trevisan, who serves as the company’s chief scientific officer.

Login

(existing subscribers)

The password field is case sensitive.
Request new password

Register for free

Sign up here for free access to 7 articles per month + twice daily business email alerts.

CAPTCHA
Thanks! This question prevents spammers...
Image CAPTCHA
Enter the characters shown in the image.

Add your comment

Share Price

Closing price for the last 90 trading days
Source: Morningstar

Total Shareholder Return as at 31/10/17

1 year TSR5 year TSR
thNeurotech International0%0%
45thMyFiziq259%0%
66thZelda Therapeutics193%24%
188thWeebit-Nano46%-19%
222ndOokami35%12%
726 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Source: Morningstar

Revenue

179th-Neurotech International$104k
182nd-Weebit-Nano$105k
183rd-Zelda Therapeutics$100k
185th-Ookami$95k
186th-MyFiziq$90k
234 listed industrial companies ranked by revenue.
Source: Morningstar

BNiQ Disclaimer